Fat-burning target found to burn calories while lying down

On November 29, the reporter learned from Jinan University (hereinafter referred to as Jinan University) that the team of Professor Yin Zhinan from the Institute of Biomedical Translation of Jinan University discovered for the first time that interleukin (IL-27) can directly target adipocytes and promote adipocytes.

"Insulin resistance is not only the cause of obesity, but also causes a series of metabolic diseases, including type 2 diabetes, fatty liver, ovarian polycystic syndrome, etc.

Yin Zhinan has been engaged in basic and clinical research on immunity and health for a long time.

"We found through clinical observations that obese patients have low levels of IL-27, but after they completed bariatric surgery, IL-27 levels returned to normal

By constructing a variety of genetically engineered mice, using a high-fat diet-induced obesity model, and combining with samples from obese people, the team found that the level of IL-27 in the serum of obese people does decrease

In animal experiments, injection of recombinant IL-27 can significantly reduce the body weight of obese mice and improve their insulin signaling sensitivity, preliminarily verifying the potential of IL-27 as a therapeutic drug

Since IL-27 is a molecule that is normally expressed in the body and is not an artificially synthesized exogenous compound, it has high safety

"We look forward to industrializing this therapeutic target as soon as possible, promoting its clinical application, developing RNA-related drugs, and providing a new treatment method for a series of metabolic diseases such as obesity, diabetes and fatty liver

However, he also emphasized that there is still a long way to go from the laboratory to the clinic, which requires the joint efforts of policy, investment and other aspects